\-\ Texto\\:\\ \ \(0\)\
\-\ hypoxic\\,\\ tachypneic\\,\\ fatigued\\ black\\ female\\ with\\ diffuse\\ crackles\\.\\ \\ cd4\\ count\\ of\\ 6\\.\ \(0\)\
\-\ the\\ patient\\â\\€\\™s\\ respiratory\\ status\\ continued\\ to\\ worsen\\ during\\ her\\ first\\ 48\\ hours\\ of\\ admission\\.\\ \\ she\\ subsequently\\ required\\ intubation\\ for\\ 5\\ days\\.\\ \\ her\\ inpatient\\ course\\ was\\ complicated\\ by\\ a\\ moderate\\ right\\-sided\\ pneumothorax\\.\\ \\ her\\ respiratory\\ symptoms\\ eventually\\ improved\\ and\\ she\\ was\\ discharged\\ to\\ home\\.\ \(0\)\
\-\ summary\\ of\\ image\\ findings\\:\\ \ \(0\)\
\-\ cxr\\:\\ \\ \ \(0\)\
\-\ unremarkable\\ chest\\ radiograph\\ obtained\\ at\\ admission\\.\ \(0\)\
\-\ frontal\\ chest\\ radiograph\\ taken\\ 48\\ hours\\ after\\ admission\\ demonstrating\\ ill\\-defined\\ ground\\ glass\\ opacities\\ within\\ the\\ bilateral\\ suprahilar\\ regions\\.\\ \\ there\\ is\\ also\\ a\\ retrocardiac\\ opacity\\.\\ \\ atypical\\ or\\ viral\\ infectious\\ process\\.\\ \\ a\\ ct\\ was\\ recommended\\.\\ \\ the\\ admission\\ chest\\ x\\-ray\\ was\\ unremarkable\\.\\ \\ \ \(0\)\
\-\ frontal\\ chest\\ radiograph\\ taken\\ at\\ 72hrs\\ demonstrates\\ interval\\ placement\\ of\\ endotracheal\\ tube\\ and\\ right\\-sided\\ central\\ venous\\ catheter\\.\\ \\ new\\ right\\-sided\\ subcutaneous\\ air\\.\\ \\ hypoinflation\\ and\\ mils\\ increased\\ interstitial\\ markings\\ of\\ the\\ lungs\\.\\ \\ \ \(0\)\
\-\ portable\\ chest\\ radiograph\\ demonstrates\\ interval\\ development\\ of\\ moderate\\ right\\-sided\\ pneumothorax\ \(0\)\
\-\ ct\\:\ \(17\)\
\-\ chest\\ ct\\ demonstrating\\ diffuse\\ patchy\\ bilateral\\ upper\\ and\\ lower\\ lobe\\ groundglass\\ opacities\\.\\ \\ differential\\ considerations\\ include\\ pcp\\ and\\ cmv\\ pneumonia\\ as\\ well\\ as\\ other\\ opportunistic\\ infection\\.\\ \\ this\\ could\\ represent\\ hypersensitivity\\ pneumonitis\\.\ \(0\)\
\-\ pcp\\ pneumonia\\ \\(pneumocystis\\ jiroveci\\ pneumonia\\)\ \(0\)\
\-\ non\\-cardiogenic\\ edema\ \(0\)\
\-\ cytomegalovirus\\ pneumonitis\ \(0\)\
\-\ diffuse\\ pulmonary\\ hemorrhage\\ syndromes\ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ pulmonary\\ alveolar\\ proteinosis\ \(1\)\
\-\ 31y\\/o\\ black\\ female\\ who\\ is\\ hiv\\ positive\\,\\ with\\ slow\\ onset\\ of\\ fatigue\\,\\ low\\ grade\\ fever\\ and\\ dyspnea\\ over\\ the\\ past\\ several\\ weeks\\.\ \(0\)\
\-\ pneumocystis\\ pneumonia\\ \\(pcp\\)\\ is\\ a\\ potentially\\ life\\-threatening\\ infection\\ that\\ occurs\\ primarily\\ in\\ immunocompromised\\ individuals\\.\\ the\\ nomenclature\\ for\\ the\\ species\\ of\\ pneumocystis\\ that\\ infects\\ humans\\ has\\ been\\ changed\\ from\\ pneumocystis\\ carinii\\ to\\ pneumocystis\\ jirovecii\\.\\ \\ typical\\ immunocompromised\\ states\\ include\\ aids\\ patients\\ with\\ cd4\\ counts\\<200\\,\\ long\\ term\\ corticosteroid\\ therapy\\,\\ organ\\ transplants\\,\\ and\\ chemotherapy\\ patients\\.\\ \\ \ \(0\)\
\-\ in\\ immunocompetent\\ patients\\ presenting\\ symptoms\\ develop\\ rapidly\\ \\(over\\ 4\\-10\\ days\\)\\;\\ and\\ include\\ hypoxia\\,\\ dry\\ cough\\,\\ and\\ fever\\.\\ \\ a\\ less\\ specific\\,\\ indolent\\ pattern\\ \\(over\\ 2\\-6\\ weeks\\)\\ is\\ more\\ common\\ in\\ immunocompromised\\ patients\\;\\ including\\ fever\\,\\ malaise\\,\\ and\\ dyspnea\\.\\ \\ \\ \\ \ \(0\)\
\-\ clinical\\ suspicion\\ should\\ be\\ high\\ in\\ a\\ hypoxic\\,\\ immunocompromised\\ patient\\ with\\ ground\\-glass\\ opacities\\ on\\ plain\\ film\\ or\\ high\\-resolution\\ ct\\.\ \(0\)\
\-\ cxr\\:\\ perihilar\\ or\\ diffuse\\ ground\\-glass\\ opacities\\ early\\,\\ which\\ can\\ advance\\ to\\ a\\ consolidative\\ appearance\\ if\\ untreated\\.\\ \\ there\\ is\\ a\\ slight\\ upper\\ lobe\\ predominance\\,\\ which\\ may\\ be\\ associated\\ with\\ prophylaxis\\ with\\ aerosolized\\ pentamidine\\.\\ \\ upper\\ lobe\\ thin\\-walled\\ cysts\\ can\\ develop\\ in\\ 30\\%\\ of\\ aids\\ patients\\,\\ which\\ can\\ result\\ in\\ pneumothorax\\.\\ \\ \ \(0\)\
\-\ uncommon\\ plain\\ film\\ findings\\ include\\ multiple\\ pulmonary\\ nodules\\ \\(some\\ of\\ which\\ may\\ cavitate\\)\\,\\ a\\ miliary\\ pattern\\,\\ reticular\\ opacities\\,\\ and\\ asymmetric\\ consolidation\\.\ \(0\)\
\-\ pleural\\ effusions\\ and\\ enlarged\\ lymph\\ nodes\\ are\\ associated\\ rarely\\.\ \(0\)\
\-\ ct\\:\\ \\ ground\\ glass\\ opacities\\ on\\ hrct\\ are\\ the\\ predominant\\ finding\\.\\ \\ superimposed\\ smooth\\ intralobular\\ and\\ interlobular\\ septal\\ thickening\\ can\\ also\\ be\\ seen\\ \\(\\â\\€\\œcrazy\\-paving\\â\\€\\\\)\\.\\ \\ upper\\ lobe\\ cysts\\ can\\ be\\ demonstrated\\ more\\ frequently\\ on\\ ct\\.\\ \\ the\\ tree\\-in\\-bud\\ pattern\\ is\\ not\\ seen\\ in\\ association\\ with\\ pneumocystis\\ pneumonia\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ bollee\\,\\ g\\,\\ sarfati\\,\\ c\\,\\ thiery\\,\\ g\\,\\ et\\ al\\.\\ clinical\\ picture\\ of\\ pneumocystis\\ jirovecii\\ pneumonia\\ in\\ cancer\\ patients\\.\\ chest\\ 2007\\;\\ 132\\:1305\\.\ \(0\)\
\-\ gurney\\,\\ jw\\.\\ \\ diagnostic\\ imaging\\:\\ chest\\.\\ \\ salt\\ lake\\:\\ amirsus\\,\\ 2006\\.\\.\ \(0\)\
\-\ thomas\\,\\ cf\\,\\ jr\\.\\,\\ limper\\,\\ ah\\.\\ pneumocystis\\ pneumonia\\.\\ n\\ engl\\ j\\ med\\ 2004\\;\\ 350\\:2487\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pneumocystis\\:\\ 0\\.08504175600687022\ \(0\)\
\-\ opacities\\:\\ 0\\.045498057115070475\ \(0\)\
\-\ pneumonia\\:\\ 0\\.04205136541938702\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.04154740287662781\ \(0\)\
\-\ jirovecii\\:\\ 0\\.029984756544103736\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.02897971534712933\ \(0\)\
\-\ right\\-sided\\:\\ 0\\.02837501717568113\ \(0\)\
\-\ chest\\:\\ 0\\.027819442177653315\ \(0\)\
\-\ pcp\\:\\ 0\\.027624086950532357\ \(0\)\
\-\ admission\\:\\ 0\\.025616751134128986\ \(0\)\
\-\ cd4\\:\\ 0\\.023366014540514235\ \(0\)\
\-\ patients\\:\\ 0\\.022567087748632916\ \(0\)\
\-\ ground\\-glass\\:\\ 0\\.020773701438313905\ \(0\)\
\-\ hypoxic\\:\\ 0\\.02055418265893441\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.020466823363434906\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.019319810231419553\ \(0\)\
\-\ radiograph\\:\\ 0\\.018516657509669132\ \(0\)\
\-\ aids\\:\\ 0\\.01819653918764208\ \(0\)\
\-\ diffuse\\:\\ 0\\.01759868993452595\ \(0\)\
\-\ g\\:\\ 0\\.01719155887167665\ \(0\)\
\-\ glass\\:\\ 0\\.01681740616686601\ \(0\)\
\-\ black\\:\\ 0\\.01674727253692473\ \(0\)\
\-\ pattern\\:\\ 0\\.016665522138118765\ \(0\)\
\-\ can\\:\\ 0\\.0164814825890227\ \(0\)\
\-\ include\\:\\ 0\\.016307166585240045\ \(0\)\
\-\ ground\\:\\ 0\\.016002192380248935\ \(0\)\
\-\ lobe\\:\\ 0\\.015641669033493427\ \(0\)\
\-\ \\:\\:\\ 0\\.015377888652934218\ \(0\)\
\-\ 72hrs\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ mils\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ 31y\\/o\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ cavitate\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ bollee\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ sarfati\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ thiery\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ 132\\:1305\\.\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ amirsus\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ limper\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ 350\\:2487\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ fever\\:\\ 0\\.01475133993138758\ \(0\)\
\-\ develop\\:\\ 0\\.014495379361788971\ \(0\)\
\-\ \\,\\:\\ 0\\.01427212930448284\ \(0\)\
\-\ interval\\:\\ 0\\.014253556498919137\ \(0\)\
\-\ 48\\:\\ 0\\.014220372230397491\ \(0\)\
\-\ upper\\:\\ 0\\.014027758539923253\ \(0\)\
\-\ fatigued\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ suprahilar\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ non\\-cardiogenic\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ infects\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ aerosolized\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ pentamidine\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ crazy\\-paving\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ gurney\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ \\;\\:\\ 0\\.013778375431650296\ \(0\)\
\-\ dyspnea\\:\\ 0\\.01375793809354025\ \(0\)\
\-\ hypoinflation\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ groundglass\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ humans\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ tree\\-in\\-bud\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ jw\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ lake\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ ah\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ her\\:\\ 0\\.013109243155535385\ \(0\)\
\-\ pulmonary\\:\\ 0\\.012737501582755426\ \(0\)\
\-\ opportunistic\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ life\\-threatening\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ nomenclature\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ 4\\-10\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ demonstrating\\:\\ 0\\.01261759506825142\ \(0\)\
\-\ cxr\\:\\ 0\\.012265415888180534\ \(0\)\
\-\ immunocompetent\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ indolent\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ intralobular\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ jr\\.\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ ct\\:\\ 0\\.012196976055020846\ \(0\)\
\-\ taken\\:\\ 0\\.012119880938502954\ \(0\)\
\-\ respiratory\\:\\ 0\\.01206687164933051\ \(0\)\
\-\ jiroveci\\:\\ 0\\.011945168290371502\ \(0\)\
\-\ 2\\-6\\:\\ 0\\.011945168290371502\ \(0\)\
\-\ thomas\\:\\ 0\\.011945168290371502\ \(0\)\
\-\ consolidative\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ engl\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ proteinosis\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ transplants\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ advance\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ salt\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ hours\\:\\ 0\\.011429242546288423\ \(0\)\
\-\ moderate\\:\\ 0\\.011429242546288423\ \(0\)\
\-\ cysts\\:\\ 0\\.011385912526637301\ \(0\)\
\-\ tachypneic\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ species\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ carinii\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ high\\-resolution\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ cf\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ film\\:\\ 0\\.011163703861357068\ \(0\)\
\-\ over\\:\\ 0\\.01110021729663246\ \(0\)\
\-\ cytomegalovirus\\:\\ 0\\.011076417229544987\ \(0\)\
\-\ miliary\\:\\ 0\\.011076417229544987\ \(0\)\
\-\ hrct\\:\\ 0\\.011076417229544987\ \(0\)\
\-\ which\\:\\ 0\\.010851323722738426\ \(0\)\
\-\ worsen\\:\\ 0\\.010630219500858778\ \(0\)\
\-\ thin\\-walled\\:\\ 0\\.010630219500858778\ \(0\)\
\-\ counts\\:\\ 0\\.010504185534610952\ \(0\)\
\-\ interlobular\\:\\ 0\\.010504185534610952\ \(0\)\
\-\ summary\\:\\ 0\\.010277091329467206\ \(0\)\
\-\ retrocardiac\\:\\ 0\\.010076780044337302\ \(0\)\
\-\ 200\\:\\ 0\\.0099848289877552\ \(0\)\
\-\ endotracheal\\:\\ 0\\.009897595493898821\ \(0\)\
\-\ perihilar\\:\\ 0\\.009897595493898821\ \(0\)\
\-\ \\.\\.\\:\\ 0\\.009659905115709777\ \(0\)\
\-\ unremarkable\\:\\ 0\\.009622674893476396\ \(0\)\
\-\ untreated\\:\\ 0\\.009587524819079169\ \(0\)\
\-\ reticular\\:\\ 0\\.009451397765212612\ \(0\)\
\-\ plain\\:\\ 0\\.009439672492139744\ \(0\)\
\-\ predominant\\:\\ 0\\.009387213533949267\ \(0\)\
\-\ cmv\\:\\ 0\\.009325363798964785\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.009325363798964785\ \(0\)\
\-\ superimposed\\:\\ 0\\.009325363798964785\ \(0\)\
\-\ intubation\\:\\ 0\\.009265684683639495\ \(0\)\
\-\ changed\\:\\ 0\\.009208028983510787\ \(0\)\
\-\ hypoxia\\:\\ 0\\.009208028983510787\ \(0\)\
\-\ frontal\\:\\ 0\\.00913024467511346\ \(0\)\
\-\ malaise\\:\\ 0\\.00909826959382104\ \(0\)\
\-\ predominance\\:\\ 0\\.00909826959382104\ \(0\)\
\-\ prophylaxis\\:\\ 0\\.00909826959382104\ \(0\)\
\-\ be\\:\\ 0\\.008964331451319245\ \(0\)\
\-\ clinical\\:\\ 0\\.008943230612469402\ \(0\)\
\-\ days\\:\\ 0\\.008908415973374073\ \(0\)\
\-\ inpatient\\:\\ 0\\.008761831254824578\ \(0\)\
\-\ alveolar\\:\\ 0\\.008676779519153384\ \(0\)\
\-\ portable\\:\\ 0\\.00863579728857675\ \(0\)\
\-\ dry\\:\\ 0\\.00863579728857675\ \(0\)\
\-\ potentially\\:\\ 0\\.008518462473122752\ \(0\)\
\-\ organ\\:\\ 0\\.008518462473122752\ \(0\)\
\-\ picture\\:\\ 0\\.008518462473122752\ \(0\)\
\-\ individuals\\:\\ 0\\.008481083380063611\ \(0\)\
\-\ infection\\:\\ 0\\.008449035966234038\ \(0\)\
\-\ crackles\\:\\ 0\\.008444508201116394\ \(0\)\
\-\ n\\:\\ 0\\.008444508201116394\ \(0\)\
\-\ considerations\\:\\ 0\\.008373636268462365\ \(0\)\
\-\ 2006\\:\\ 0\\.008373636268462365\ \(0\)\
\-\ med\\:\\ 0\\.008339277922684272\ \(0\)\
\-\ syndromes\\:\\ 0\\.008305599985105735\ \(0\)\
\-\ weeks\\:\\ 0\\.008249244071092341\ \(0\)\
\-\ ill\\-defined\\:\\ 0\\.008208391798303101\ \(0\)\
\-\ 2007\\:\\ 0\\.008208391798303101\ \(0\)\
\-\ she\\:\\ 0\\.00815913653555841\ \(0\)\
\-\ markings\\:\\ 0\\.00805779078241629\ \(0\)\
\-\ hiv\\:\\ 0\\.00805779078241629\ \(0\)\
\-\ rapidly\\:\\ 0\\.00805779078241629\ \(0\)\
\-\ eventually\\:\\ 0\\.008001096190124467\ \(0\)\
\-\ septal\\:\\ 0\\.007919447858174875\ \(0\)\
\-\ slow\\:\\ 0\\.007867115105340258\ \(0\)\
\-\ 2004\\:\\ 0\\.007816344759847604\ \(0\)\
\-\ patchy\\:\\ 0\\.0077915168696755755\ \(0\)\
\-\ fatigue\\:\\ 0\\.007767046227750236\ \(0\)\
\-\ primarily\\:\\ 0\\.007627185516462869\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.007561344509352852\ \(0\)\
\-\ complicated\\:\\ 0\\.0075399520226064895\ \(0\)\
\-\ suspicion\\:\\ 0\\.0075399520226064895\ \(0\)\
\-\ effusions\\:\\ 0\\.0074169577001921595\ \(0\)\
\-\ \\(\\:\\ 0\\.007371038022896535\ \(0\)\
\-\ viral\\:\\ 0\\.0073208484990640275\ \(0\)\
\-\ consolidation\\:\\ 0\\.007283875732675581\ \(0\)\
\-\ \\)\\:\\ 0\\.007280996858299031\ \(0\)\
\-\ more\\:\\ 0\\.007269307174531178\ \(0\)\
\-\ symptoms\\:\\ 0\\.007243732914619521\ \(0\)\
\-\ interstitial\\:\\ 0\\.007110186115198746\ \(0\)\
\-\ uncommon\\:\\ 0\\.007110186115198746\ \(0\)\
\-\ 6\\.\\:\\ 0\\.007061359404514339\ \(0\)\
\-\ asymmetric\\:\\ 0\\.007061359404514339\ \(0\)\
\-\ association\\:\\ 0\\.007061359404514339\ \(0\)\
\-\ bilateral\\:\\ 0\\.007053801800389265\ \(0\)\
\-\ catheter\\:\\ 0\\.006982973167779191\ \(0\)\
\-\ rarely\\:\\ 0\\.0069677203276724544\ \(0\)\
\-\ improved\\:\\ 0\\.0069227658088490615\ \(0\)\
\-\ home\\:\\ 0\\.006908041212347166\ \(0\)\
\-\ c\\:\\ 0\\.006908041212347166\ \(0\)\
\-\ associated\\:\\ 0\\.006858716196964972\ \(0\)\
\-\ states\\:\\ 0\\.006836271901989382\ \(0\)\
\-\ slight\\:\\ 0\\.006836271901989382\ \(0\)\
\-\ opacity\\:\\ 0\\.006794620507417451\ \(0\)\
\-\ was\\:\\ 0\\.006722976341589706\ \(0\)\
\-\ discharged\\:\\ 0\\.006662718748325827\ \(0\)\
\-\ regions\\:\\ 0\\.006650074227088552\ \(0\)\
\-\ term\\:\\ 0\\.006650074227088552\ \(0\)\
\-\ subsequently\\:\\ 0\\.006588224492104071\ \(0\)\
\-\ nodes\\:\\ 0\\.006564100963206186\ \(0\)\
\-\ j\\:\\ 0\\.006564100963206186\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.006552166315827535\ \(0\)\
\-\ represent\\:\\ 0\\.006382522773706686\ \(0\)\
\-\ may\\:\\ 0\\.006375266560877972\ \(0\)\
\-\ smooth\\:\\ 0\\.006361130286960325\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006349051706303353\ \(0\)\
\-\ development\\:\\ 0\\.006329537794489346\ \(0\)\
\-\ count\\:\\ 0\\.006319136047861053\ \(0\)\
\-\ atypical\\:\\ 0\\.006298521489132576\ \(0\)\
\-\ frequently\\:\\ 0\\.006298521489132576\ \(0\)\
\-\ continued\\:\\ 0\\.006258027188633055\ \(0\)\
\-\ infectious\\:\\ 0\\.006248052495686799\ \(0\)\
\-\ findings\\:\\ 0\\.006186520189761767\ \(0\)\
\-\ al\\:\\ 0\\.006160819001830422\ \(0\)\
\-\ tube\\:\\ 0\\.006123439908771279\ \(0\)\
\-\ a\\:\\ 0\\.00607040512987655\ \(0\)\
\-\ references\\:\\ 0\\.0060422248895605655\ \(0\)\
\-\ recommended\\:\\ 0\\.006024691947963863\ \(0\)\
\-\ nodules\\:\\ 0\\.006024691947963863\ \(0\)\
\-\ specific\\:\\ 0\\.006007337917055288\ \(0\)\
\-\ female\\:\\ 0\\.0059753750729518145\ \(0\)\
\-\ occurs\\:\\ 0\\.0059647121200090015\ \(0\)\
\-\ et\\:\\ 0\\.005947956513813404\ \(0\)\
\-\ presenting\\:\\ 0\\.005923128623641376\ \(0\)\
\-\ placement\\:\\ 0\\.0058986579817160364\ \(0\)\
\-\ lymph\\:\\ 0\\.005866568722694977\ \(0\)\
\-\ typical\\:\\ 0\\.005827290296173465\ \(0\)\
\-\ diagnostic\\:\\ 0\\.005758797270428669\ \(0\)\
\-\ seen\\:\\ 0\\.005743631343767653\ \(0\)\
\-\ is\\:\\ 0\\.005737661003925771\ \(0\)\
\-\ in\\:\\ 0\\.005733295648166733\ \(0\)\
\-\ also\\:\\ 0\\.005729998617925685\ \(0\)\
\-\ pleural\\:\\ 0\\.005643452718832136\ \(0\)\
\-\ \\<\\:\\ 0\\.005608954978744541\ \(0\)\
\-\ process\\:\\ 0\\.005595349464004616\ \(0\)\
\-\ 30\\:\\ 0\\.005588587306896386\ \(0\)\
\-\ result\\:\\ 0\\.005575143124061159\ \(0\)\
\-\ cough\\:\\ 0\\.00556846067824502\ \(0\)\
\-\ grade\\:\\ 0\\.0055354367227057315\ \(0\)\
\-\ lungs\\:\\ 0\\.005503041833299789\ \(0\)\
\-\ course\\:\\ 0\\.005483897012679662\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.0054277226492842855\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.0053972982194360275\ \(0\)\
\-\ could\\:\\ 0\\.0053614931017526395\ \(0\)\
\-\ early\\:\\ 0\\.005314896206874894\ \(0\)\
\-\ venous\\:\\ 0\\.005275145609620968\ \(0\)\
\-\ including\\:\\ 0\\.005247310613933544\ \(0\)\
\-\ required\\:\\ 0\\.005230825700318476\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.005209091471328002\ \(0\)\
\-\ status\\:\\ 0\\.005187631498608254\ \(0\)\
\-\ obtained\\:\\ 0\\.0051664389468432685\ \(0\)\
\-\ or\\:\\ 0\\.0051098099436923845\ \(0\)\
\-\ new\\:\\ 0\\.005064265266667616\ \(0\)\
\-\ that\\:\\ 0\\.005020342614145658\ \(0\)\
\-\ long\\:\\ 0\\.005010580800735924\ \(0\)\
\-\ enlarged\\:\\ 0\\.00495853923534695\ \(0\)\
\-\ thickening\\:\\ 0\\.004926232261383251\ \(0\)\
\-\ less\\:\\ 0\\.0049216666740181676\ \(0\)\
\-\ air\\:\\ 0\\.004917113310462527\ \(0\)\
\-\ first\\:\\ 0\\.004876672508139205\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.00483717106152387\ \(0\)\
\-\ central\\:\\ 0\\.004781685981054352\ \(0\)\
\-\ cancer\\:\\ 0\\.0047774919461985805\ \(0\)\
\-\ positive\\:\\ 0\\.004715791820211083\ \(0\)\
\-\ finding\\:\\ 0\\.004683778069793336\ \(0\)\
\-\ several\\:\\ 0\\.004671926591364605\ \(0\)\
\-\ should\\:\\ 0\\.00463300772430068\ \(0\)\
\-\ past\\:\\ 0\\.004617686176779649\ \(0\)\
\-\ differential\\:\\ 0\\.0046138772608043015\ \(0\)\
\-\ onset\\:\\ 0\\.004587451064498554\ \(0\)\
\-\ image\\:\\ 0\\.004539437357648981\ \(0\)\
\-\ during\\:\\ 0\\.004447294642727565\ \(0\)\
\-\ some\\:\\ 0\\.004413143288889046\ \(0\)\
\-\ as\\:\\ 0\\.004396522128891591\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.004343582890553496\ \(0\)\
\-\ there\\:\\ 0\\.004325563117227853\ \(0\)\
\-\ demonstrated\\:\\ 0\\.004264319698056067\ \(0\)\
\-\ 5\\:\\ 0\\.004251973507558101\ \(0\)\
\-\ s\\:\\ 0\\.004167972222983991\ \(0\)\
\-\ appearance\\:\\ 0\\.004156303701929662\ \(0\)\
\-\ edema\\:\\ 0\\.004110414097672263\ \(0\)\
\-\ low\\:\\ 0\\.004041102130725169\ \(0\)\
\-\ and\\:\\ 0\\.003979790943059252\ \(0\)\
\-\ high\\:\\ 0\\.003977119151491183\ \(0\)\
\-\ are\\:\\ 0\\.003962156029012251\ \(0\)\
\-\ been\\:\\ 0\\.003953732805210869\ \(0\)\
\-\ if\\:\\ 0\\.003943441213912645\ \(0\)\
\-\ at\\:\\ 0\\.003937969907590588\ \(0\)\
\-\ therapy\\:\\ 0\\.0038854435310214505\ \(0\)\
\-\ common\\:\\ 0\\.0038031755305380902\ \(0\)\
\-\ who\\:\\ 0\\.0037890619203090167\ \(0\)\
\-\ on\\:\\ 0\\.003693321491660347\ \(0\)\
\-\ increased\\:\\ 0\\.003555246227550435\ \(0\)\
\-\ imaging\\:\\ 0\\.0034048874565571472\ \(0\)\
\-\ \\%\\:\\ 0\\.0033900017573911694\ \(0\)\
\-\ other\\:\\ 0\\.003349725422963348\ \(0\)\
\-\ well\\:\\ 0\\.003287552641103148\ \(0\)\
\-\ lower\\:\\ 0\\.003268472907081399\ \(0\)\
\-\ multiple\\:\\ 0\\.003060894563740253\ \(0\)\
\-\ after\\:\\ 0\\.0030068047663421808\ \(0\)\
\-\ patient\\:\\ 0\\.0029135779963142447\ \(0\)\
\-\ to\\:\\ 0\\.002905225227503308\ \(0\)\
\-\ within\\:\\ 0\\.0027723323271872137\ \(0\)\
\-\ has\\:\\ 0\\.002729081582473262\ \(0\)\
\-\ for\\:\\ 0\\.0024799596892609355\ \(0\)\
\-\ by\\:\\ 0\\.0024198484749062494\ \(0\)\
\-\ \\.\\:\\ 0\\.002414934428390903\ \(0\)\
\-\ of\\:\\ 0\\.002179492872071212\ \(0\)\
\-\ from\\:\\ 0\\.002153802233255463\ \(0\)\
\-\ the\\:\\ 0\\.0021160604801575378\ \(0\)\
\-\ not\\:\\ 0\\.0021000317546631554\ \(0\)\
\-\ this\\:\\ 0\\.0016345870974730154\ \(0\)\
\-\ with\\:\\ 0\\.0013929068582129729\ \(0\)\
